Navigation Links
Depolarization-induced suppression of inhibition


Depolarization-induced suppression of inhibition (DSI) is the classical and original electrophysiological example of endocannabinoid function in the central nervous system. Prior to the demonstration that DSI was dependent on the cannabinoid CB1 receptor function, there was no way of producing an in vitro endocannabinoid mediated effect.

DSI is classically produced in a brain slice experiment (i.e. a 300-400 µm slice of brain, with intact axons and synapses) where a single neuron is "depolarized" (the normal −70 mV potential across the neuronal membrane is reduced, usually to −30 to 0 mV) for a period of 1 to 10 seconds. After the depolarization, inhibitory GABA mediated neurotransmission is reduced. This has been demonstrated to be caused by the release of endogenous cannabinoids from the depolarized neuron which diffuses to nearby neurons, and binds and activates CB1 receptors, which act presynaptically to reduce neurotransmitter release.

Contents

History

DSI was discovered in 1992 by two different laboratories (Pitler & Alger, 1992; Vincent et al, 1992), one working with pyramidal cells in the hippocampus and another working with Purkinje cells in the cerebellum.

These groups were studying the responses of large pyramidal projection neurons to GABA, the main inhibitory neurotransmitter in the central nervous system. GABA is typically released by small interneurons in many regions of the brain, where its job is to inhibit the activity of primary neurons, such as the CA1 pyramidal neurons of the hippocampus or the Purkinje cells of the cerebellum. Activation of GABA receptors on these cells, whether they are ionotropic or metabotropic, typically results in the influx of chloride ions into that target cell. This build-up of negative charge from the chloride ions results in the hyperpolarization of the target cell, making it less likely to fire an action potential. Accordingly, any ionic current that hyperpolarizes a cell is called an inhibitory current.

In their experiments with projection neurons in the hippocampus and cerebellum, both groups noticed that a train of action potentials in these cells resulted in a temporary reduction in inhibitory currents caused by GABA-ergic interneurons. Since this reduction of inhibitory currents could be invoked simply by depolarization of the target cell, this phenomenon was termed depolarization-induced suppression of inhibition, or DSI. While initially discovered in CA1 neurons of the hippocampus and Purkinje cells in the cerebellum, DSI is a pretty ubiquitous phenomenon and has been demonstrated in other areas of the brain such as the basal ganglia, the cortex, the amygdala, and the hypothalamus (Katona et al. 2001, Jo et al. 2005, Bodor et al. 2005, Matyas et al. 2006)

DSI mediation by endocannabinoids

DSI was thought to be due to a reduction in pre-synaptic neurotransmitter release for 2 reasons. 1) The magnitudes of spontaneously evoked inhibitory post-synaptic currents (IPSCs), caused by the release of a single pre-synaptic vesicle filled with GABA, remained unchanged and 2) The cellular responses to exogenously applied GABA remained the same. These observations suggested that no changes occurred in the post-synaptic cell to change its responsiveness to GABA during DSI. Somehow, DSI appeared to be mediated by a retrograde synaptic messenger whose synthesis or release was stimulated by the depolarization of the target cell. This messenger then diffused "backwards" to the pre-synaptic cell, where it caused a reduction in neurotransmitter release.

The chemical messengers presumed to be responsible for mediating DSI was discovered by three separate groups in 2001. Wilson & Nicoll (2001) published their work in the prestigious journal, Nature, while the other two groups, Kreitzer & Regehr (2001) and Ohno-Shosaku et al. (2001), published in the same issue of another reputable journal, Neuron. All three demonstrated heavy involvement of the CB1 cannabinoid receptor in DSI, suggesting that the endocannabinoids were the brain's mediators of DSI. They showed that cannabinoid receptor agonists, drugs that mimic the actions of endocannabinoids or THC, could evoke the same reduction in inhibitory currents caused by DSI. They also demonstrated that DSI could be prevented by cannabinoid receptor antagonists, drugs that block the actions of cannabinoid compounds.

Other lines of evidence support the role of the CB1 receptor in DSI. This receptor is distributed very widely throughout the brain, covering all areas where DSI has been observed (Herkenham et al. 1990). The CB1 receptor also appears to be expressed mainly on GABA-ergic pre-synaptic terminals, making it an excellent candidate for mediating DSI (Matyas et al. 2006, Katona et al. 1999). In 2005, other groups began to demonstrate the involvement of the CB1 receptor in DSI in other regions of the brain (Jo et al. 2005, Bodor et al. 2005). Lastly, DSI research was finally applied to mice that had the CB1 receptor genetically "knocked-out". So far, these knock-out mice are not known to exhibit DSI in any regions of the brain, suggesting that the CB1 receptor is the crucial mediator for DSI (Kreitzer & Regehr 2001a, Ohno-Shosaku et al. 2002).

The discovery that DSI is mediated by endocannabinoids finally explained why both the CB1 receptor and the endocannabinoids are both so widely distributed in the brian. DSI is a very common form of short-term plasticity and thus needs to be mediated by a commonly found neurotransmitter. The use of endocannabinoids such as anandamide and 2-arachidonoyl glycerol in this method of signalling is quite logical, since both molecules can be synthesized relatively easily from lipids in the plasma membrane, a fundamental constituent of all cells. DSI is therefore the primary cortical process mediated by the endocannabinoids, and may contribute to many forms of cortical plasticity and synaptic strengthening, such as in long-term potentiation (Carlson et al. 2002).

A note on DSE

While working with the cerebellum, Kreitzer's group also discovered that depolarization of Purkinje cells could also cause a temporary reduction in excitatory input into these cells from both climbing fibres and parallel fibres (Kreitzer et al. 2001b). This phenomenon was termed depolarization-induced suppression of excitation (DSE), and differs from DSI only by the kind of neurotransmitter whose release is reduced. In the case of DSI, the result is a reduction in inhibitory GABA release, while in DSE the effect is a reduction in excitatory glutamate release. DSE was also found to occur in other regions of the brain, however the evidence for the involvement of the endocannabinoid receptor CB1 in this process is not as solid as it is for DSI. Both DSI and DSE have been studied in the CB1 knock-out mice. Some groups show that both DSI and DSE are lacking in these mice, while others have shown that DSE, but not DSI, can still be evoked in the knock-outs (Ohno-Shosaku et al. 2002, Hajos et al. 2001). The endocannabinoids may still mediate DSE too, but by acting at an as-of-yet unknown cannabinoid receptor. Interestingly, some work has shown that anandamide can bind to the vannilloid receptor VR1, known as the capsaicin receptor. This receptor is present in the brain, and anandamide actions at this receptor may potentially contribute to DSE (Cristino et al. 2006, Hajos et al. 2002). However DSE is currently a largely unexplored phenomenon and more research is needed to draw any firm conclusions.

References

  • Bodor AL, Katona I, Nyiri G, Mackie K, Ledent C, Hajos N, Freund TF. (2005) Endocannabinoid signaling in rat somatosensory cortex: laminar differences and involvement of specific interneuron types. J Neurosci. Jul 20;25(29):6845-56.
  • Carlson G, Wang Y, Alger BE. (2002) Endocannabinoids facilitate the induction of LTP in the hippocampus. Nat Neurosci. Aug;5(8):723-4.
  • Cristino L, de Petrocellis L, Pryce G, Baker D, Guglielmotti V, Di Marzo V. (2006) Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience. Apr 5; In Press.
  • Hajos N, Freund TF. (2002) Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuropharmacology. Sep;43(4):503-10.
  • Hajos N, Ledent C, Freund TF. (2001) Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience. 106(1):1-4.
  • Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC. (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A. Mar;87(5):1932-6.
  • Jo YH, Chen YJ, Chua SC Jr, Talmage DA, Role LW. (2005) Integration of endocannabinoid and leptin signaling in an appetite-related neural circuit. Neuron. Dec 22;48(6):1055-66.
  • Katona I, Rancz EA, Acsady L, Ledent C, Mackie K, Hajos N, Freund TF. (2001) Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci. Dec 1;21(23):9506-18.
  • Katona I, Sperlagh B, Sik A, Kafalvi A, Vizi ES, Mackie K, Freund TF. (1999) Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci. Jun 1;19(11):4544-58.
  • Kreitzer AC, Regehr WG. (2001a). Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron. 29(3):717-27
  • Kreitzer AC, Regehr WG. (2001b) Cerebellar depolarization-induced suppression of inhibition is mediated by endogenous cannabinoids. J Neurosci. Oct 15;21(20):RC174.
  • Matyas F, Yanovsky Y, Mackie K, Kelsch W, Misgeld U, Freund TF. (2006) Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience.137(1):337-61.
  • Ohno-Shosaku T, Tsubokawa H, Mizushima I, Yoneda N, Zimmer A, Kano M. (2002) Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses. J Neurosci. May 15;22(10):3864-72.
  • Ohno-Shosaku T, Maejima T, Kano M. (2001) Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron. 29(3):729-38
  • Pitler TA, Alger BE. (1992). Postsynaptic spike firing reduces synaptic GABAA responses in hippocampal pyramidal cells. J Neurosci 12:4122-4132.
  • Vincent P, Armstrong CM, Marty A. (1992) Inhibitory synaptic currents in rat cerebellar Purkinje cells: modulation by postsynaptic depolarization. J. Physiol. (London) 456, p. 453–471.
  • Wilson RI, Nicoll RA. (2001) Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature. 410(6828):588-92

Further reading

  • Alger BE. (2002). Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog Neurobiol 68:247-286.
  • Freund TF, Katona I, Piomelli D. (2003). Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83:1017-1066.

'"/>


(Date:8/21/2014)... Albany, Ohio (PRWEB) August 21, 2014 ... that he took his own life by hanging, likely ... Sharry Edwards, the foremost BioAcoustic Vocal Profiling ... show offering novel information concerning Williams’ death; hoping to ... Several issues relevant to Williams’ suicide were proposed ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 The costs paid ... continue to rise, according to insurer data. The Quotes Pros ... in real time using its tools at http://quotespros.com . ... the company homepage connects with providers offering multiple coverage packages ... are promoted to the public are now easier to compare ...
(Date:8/21/2014)... Today, Zane Benefits, the #1 Online Health ... credits in 2015. , According to Zane Benefits, premium ... Affordable Care Act (ACA), premium tax credits are available ... through the Health Insurance Marketplaces. , The new article ... of the tax credits, updated for 2015. , ...
(Date:8/21/2014)... chronic kidney disease patients may be a strong indicator ... in the Journal of the American Society of ... Hopkins Bloomberg School of Public Health assert that coronary ... atherosclerosis in predicting the risk of heart disease among ... all patients with chronic kidney disease (CKD) die from ...
(Date:8/21/2014)... Texas MD Anderson Cancer Center today announced a new ... screening at a network of community breast care centers ... November, MD Anderson will become the exclusive provider of ... 10 breast care centers, located in Memorial City, The ... the network will expand to Memorial Hermann,s locations in ...
Breaking Medicine News(10 mins):Health News:Robin Williams: What he could not bear to face 2Health News:Robin Williams: What he could not bear to face 3Health News:Dental Insurance Now Quoted for Families Online at Insurer Portal 2Health News:Measuring calcium buildup to predict heart disease in those with chronic kidney disease 2Health News:MD Anderson and Memorial Hermann to operate breast screening network across Houston area 2
... of Pittsburgh in USA, charged with causing involuntary manslaughter of ... gone to a bar, leaving the children unattended. ... "God Loves You More," Shakita Mangham, 25, arrived at municipal ... headquarters a short time later. They are being charged with ...
... Researchers have designed a pair of new vaccines that not ... withdrawal symptoms. ,The study was conducted by ... Jay H. Waggoner at Baylor College of Medicine (BCM). ... of the vaccines on subjects administered to it. ...
... decline, thanks to the comprehensive program in 2002, encouraging smokers ... report shows a decline in the smoking rate by 20%, ... smoking decreased among men (from 22.5% to 19.9%) and among ... year-long ad campaign aimed at prompting more smokers to quit. ...
... count up to ten, identified colours and even dabbled with ... IQ test that her soaring brainpower was established. ... the youngest female celebrated member of Mensa. ,The youngest ... been described by Britain's leading expert on intelligent children as ...
... Grunenthal GmbH presented the first clinical evidence for ... release) for patients suffering from chronic pain ... Against Rheumatism (EULAR), 13-16 June 2007, Barcelona, Spain. ... of its kind, combining two analgesic principles, mu-receptor ...
... new modified drug for Alzheimers disease.The drug has begun ... of people suffer from this devastating disease and treatment options ... led the creation of the treatment molecule. "Current drugs manage ... It may be able to prevent and reverse the disease." ...
Cached Medicine News:Health News:Mothers of Children Killed in Fire Charged With Manslaughter 2Health News:Mothers of Children Killed in Fire Charged With Manslaughter 3Health News:New York Records Decline in Smoking Rate 2Health News:Two-year-old Joins Mensa, Becomes Its Youngest Ever Genius 2Health News:Phase II Data Show Efficacy and Tolerability of Tapentadol in Chronic Pain Treatment 2Health News:Phase II Data Show Efficacy and Tolerability of Tapentadol in Chronic Pain Treatment 3Health News:Modified Drug Therapy for Alzheimers Disease 2
Other medicine definitionOther Tags